Hepatitis C is an infection of the liver caused by the virus called Hepatitis C Virus (HCV). Hepatitis C can be acute and chronic, it is an asymptomatic disease, but a chronic infection can be life threatening and cause serious health complications in the future and eventually death. Many are unaware of this infection; the life threatening health risk involves liver damage, end- stage liver disease and hepatocellular carcinoma and even death. It 's been estimated that in the United States 2.7 million people are infected with chronic HCV, whereas the Centers for Disease Control and Prevention (CDC) estimates 3.2 million (Ditah, 2010). The infected population are primarily in their fifties and sixties, born between 1945 and 1965. One attributable cause is believed to be the transmission of the contaminated blood through organ transplants and drug injections. It is expected that compensated cirrhosis and Hepatocellular Carcinoma (HCC) will increase by over 80 percent from the year 2000 to the year 2020. Over the same period, it is estimated that decompensated cirrhosis would increase over 100 percent and that liver-related deaths would increase by 181 percent (Davis GL, Albright JE, 2003). This topic is important because since Hepatitis C is asymptomatic disease it has been estimated that approximately 50% of people living with HCV are unaware that they are infected. The World Health Organization (WHO) in 2014 estimated that more than 180 million people worldwide are infected
As alarming as this may sound, this does affect you in your daily lives. A majority of the people reading this piece may be healthy beings, but there are no guarantees that this may not affect us in the future. Then again, other than hepatitis C, there are numerous other illnesses such as rheumatoid arthritis that we may encounter later in our lives. These diseases also have an alarming price tag associated with its treatments or medications.
This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.
A few years ago, Hepatitis C was a scary term for many of us. But, today the medical problem is curable as there are various and advanced ways available. The improvement in the treatment is especially notable because experts have worked harder to obtain this success. Still, there are some significant changes are left and hopefully they will be completed soon. Presently, the HCV treatments get rid of the virus in merely slightly more than half of all sufferers. The medicines also have unnecessary side effects that make it complicated or not possible for some patients to get them. HCV medication online available, but it is not worthy to take them without the concern of the doctor.
Hepatitis C has been referred to as a "Silent Epidemic," since it usually progresses slowly over many years. Most people who are infected with hepatitis C are not aware of any noticeable symptoms for as long as one to two decades after they are infected. In fact, by the time symptoms appear, the virus has probably already begun to damage the liver. If the liver is injured and stops functioning, death will always be the outcome (Lieber). Liver failure from chronic hepatitis C is one of the most common causes of liver transplants in the United States.
Liver cirrhosis, which is the end product of liver disease caused by HCV, is the leading cause of organ transplants in the United States (Hirsch, 2000).
Based on the Scientific Registry of Transplant Recipients (SRTR), the number of waitlisted older adults (> 65 years) for liver transplantation has significantly increased in the past decade from 9.9% (1,637) in 2001 to 16% (2,460) in 2011 (22). The demand for liver transplantation is expected to increase with high rates of Hepatitis C infection among individuals born between 1945- 1965 who are at risk for cirrhosis and hepatocellular carcinoma (HCC) (23). Given the increasing numbers
Hepatitis is inflammation of the liver. There are currently five known viruses that cause can hepatitis (Microbiology, 10e). The hepatitis C virus (HCV) is transmitted through contact with the blood of an infected person; however, it is now more commonly spread among IV drug users that share needles. Healthcare workers are also at risk for contracting HCV, but with standard precautions, the risk is low. “Prior to 1992, some people acquired the HCV infection from transfusions of blood or blood products. Since 1992, all blood products have been screened for HCV, and cases of HCV due to blood transfusion now are extremely rare. HCV can be passed from mother to unborn child. Approximately 4 out of every 100 infants born to HCV-positive mothers
Recall the dreaded trips to the doctor’s office when it was time to get shots. These shots are vaccines, which provide immunity to certain diseases. You received vaccines for Tetanus, Hepatitis B, Measles and Polio. A vaccine you did not get though, is one for Hepatitis C. Hepatitis C is a disease that affects the way the liver operates, and although there is a vaccine for both Hepatitis A and B, there is not one for C. Hepatitis C affects the digestive system, more specifically the liver. It can also damage the central nervous system and the circulatory system. Blood tests are the most common way to detect Hepatitis C and after one has been diagnosed with it, there are many ways to treat it. Hepatitis C is a treatable disease with varying
About 4.1 million people in Americans have the positive antibody to hepatitis C virus (HCV), and about 75 percent have permeant infection. Additionally, most of the infections happened 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk of severe complications in the infected people. Identification, death, and treatment are predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials (Kalichman, Washington, Kegler, Grebler, Kalichman, Cherry, & Eaton, 2015). The CDC recommends a HCV one time test for people born between 1945 and 1965. The objective of this study was to thoroughly evaluate the amount of substance abusers infected with hepatitis C in the United States. Additionally, to observe the treatment of HCV. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states, including the District of Columbia. Medicaid and Medicare covered the drug based on the following conditions; liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74 percent for the drug sofobuvir. About two-thirds of the United States restricted the treatment centered on prescriber type. About 88 percent included drug abuse in their sofosbuvir admissibility measures. Finally, 50 percent required a date of abstinence and 64 percent required
About 4.1 million people in Americans have the positive antibody for hepatitis C virus (HCV), and about 75% of them are persistently infected and most of the infections happened d 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk for severe complications in the infected people. Identification, death, and treatment is predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials. The CDC recommends a HVC one time test for people born between 1945 and 1965.They observed testing by birth. The objective of this study was to thoroughly evaluate the amount of substance abuser infected with hepatitis C in the United States. Additional to observe the treatment of HVC. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states including the District of Columbia. Medicaid and Medicare covered the drug based on the following classes liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74% for the drug sofobuvir. About two thirds of the United States restricted the treatment centered on prescriber type. About 88% included drug abuse in their sofosbuvir admissibility measures. Finally 50% required a dated of abstinence and 64% required drug test. The latest drug to HVC is called Sovaldi and it costs $84,000 for the 12
Hepatitis C has developed into a significant public health issue that poses challenges because of the nature of its gestation period. The disease is asymptomatic so persons that have the disease might appear healthy for years unaware that they have the infection. The difference in genotypes in relation to diagnosis also presents another challenge to doctors. However, with improved techniques of disease diagnosis, it will be easier to detect the disease in its early stages of development which will prevent severe damage to the liver that only occurs when the disease has advanced to worse states. Liver cirrhosis and hepatomas are common problems that occur in patients when the diagnosis is confirmed at late stages.
Hepatitis C viral (HCV) infection is one of the many chronic illnesses that disproportionately affect the 2 million persons currently incarcerated in US jails and prisons. (ACA, 2015). HCV is most frequently acquired through exposure to infected blood in persons who injected drugs any time in their lifetime. Offenders are statistically at increased risk for bloodborne pathogen infections such as HCV because of the strong association of chronic addiction and criminal behavior. Correctional health care systems have more patients with HCV infection, on a percentage basis, than any other major health care system in the United States.
Hepatitis C (HCV) is a blood borne virus that can lead to chronic liver disease and liver failure. In Canada, nearly 250,000 people have an active Hepatitis C infection (Strike, Leonard, Millson, Anstice, Berkeley, & Medd, 2006). People who inject drugs (PWID) are disproportionately represented in this statistic accounting for over 66% of those infected (Strike et al., 2006). Needle sharing among PWID is oft cited as one of the leading causes of HCV transmission (Strike et al. 2006).
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which can cause both acute and chronic hepatitis infection, which are the two major types of hepatitis C. Ranging in seriousness from a mild illness lasting a few weeks to a major illness that can last a lifetime, hepatitis c often leads to inflammation of the liver. It is a problem in the United States and worldwide, mostly affecting Africa and Central and East Asia. HCV is responsible for 500,000 liver related deaths each year, is the most common bloodborne pathogen, and is a leading cause of liver transplantation. More than 4 million people in the Unites States are infected and most are not even aware of their diagnosis. Also, death due to HCV infection is the most
The Egyptian Demographic Health Survey (EDHS), a cross sectional survey was done on a big sample of Egyptian people in age group from 15 to59 years to measure hepatitis C prevalence and it was 14.7%. In comparison to HCV studies conducted in different countries and reported that Egypt has the largest epidemic of (HCV) all over the world (El-Zanaty and Way, 2009).